NDAORALTABLET
Approved
Dec 2015
Lifecycle
Peak
Competitive Pressure
0/100
Clinical Trials
2
Data completeness
3/8 — Basic
Drug data last refreshed 7h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
ZURAMPIC (lesinurad) is an oral small-molecule urate transporter 1 (URAT1) inhibitor approved in December 2015 for chronic gout management. It is typically used as an adjunct to xanthine oxidase inhibitors (XOIs) in patients who do not achieve target serum uric acid levels with XOI monotherapy alone. The drug works by blocking renal reabsorption of uric acid, increasing urinary excretion and lowering serum uric acid concentrations.
Peak5.7 years to LOE
Product is in peak commercial stage with established market presence; brand teams are focused on market maintenance and managed care optimization.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (2)
Post-Authorisation Safety Study of Lesinurad
Started Jan 2021
0GoutHyperuricemia
A Phase 4 Safety and Efficacy Study to Evaluate Lesinurad 200 mg in Participants With Gout and Renal Impairment
Started Jul 2017
242 enrolled
GoutChronic Kidney Disease (CKD)
Career Relevance
ZURAMPIC offers career opportunities primarily in commercial execution and market access roles within the gout therapeutic area. With peak-stage lifecycle status and strong patent protection through 2032, the product provides stable employment in brand management, sales, and managed care strategy.
Brand Manager
Worked on ZURAMPIC at Ironwood Pharmaceuticals? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.